Group 1 - The company Hai Zheng Sheng Cai announced on February 2 that as of January 31, 2026, it has repurchased approximately 2.19 million shares through the Shanghai Stock Exchange, accounting for 1.078% of its total share capital of approximately 203 million shares [1] - The highest repurchase price was 15.98 yuan per share, while the lowest was 7.76 yuan per share, with a total expenditure of approximately 24.22 million yuan [1] Group 2 - The automotive sales giant Baolide, known for selling luxury cars such as Rolls-Royce and Porsche, is now undergoing bankruptcy liquidation, with its headquarters in Hangzhou reportedly vacant and its subsidiary in Yiwu sealed [1]

证券之星消息，2月2日化学制药板块较上一交易日下跌2.74%，常山药业领跌。当日上证指数报收于 4015.75，下跌2.48%。深证成指报收于13824.35，下跌2.69%。化学制药板块个股涨跌见下表： 从资金流向上来看，当日化学制药板块主力资金净流出17.84亿元，游资资金净流入4.59亿元，散户资金 净流入13.25亿元。化学制药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002099 海翔药业 | | 8825.41万 | 12.82% | -5616.28万 | -8.16% | -3209.13万 | -4.66% | | 300436 | 广生堂 | 7859.33万 | 6.93% | -2678.33万 | -2.36% | -5181.00万 | -4.57% | | 600513 联环药业 | | 3551.00万 | 13.02% | -876.01万 | -3. ...

Core Viewpoint - The company, Hai Zheng Sheng Cai (688203.SH), has announced a share buyback program, indicating a commitment to returning value to shareholders and potentially signaling confidence in its future performance [1] Group 1: Share Buyback Details - As of January 31, 2026, the company has repurchased a total of 2,185,500 shares, which represents 1.078% of its current total share capital [1] - The highest price paid for the repurchased shares was 15.98 CNY per share, while the lowest price was 7.76 CNY per share [1] - The total amount spent on the share buyback was 24,215,121.30 CNY, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The company, Haizheng Shengcai (688203.SH), has announced a share buyback program, having repurchased a total of 2.1855 million shares as of January 31, 2026, which represents 1.078% of its total share capital of 203 million shares [1] - The highest price at which the shares were repurchased was 15.98 RMB per share, while the lowest price was 7.76 RMB per share [1] - The total amount spent on the share buyback was 24.2151 million RMB, excluding transaction fees such as stamp duty and trading commissions [1]

证券日报网讯2月2日，北陆药业（300016）在互动平台回答投资者提问时表示，公司2024年度实现海外 营业收入13216.14万元，同比增长15.02%；2025年上半年实现海外营业收入7429.24万元，同比增长 30.41%。2025年度海外销售数据将在公司《2025年年度报告》中详细披露。 ...

1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 来源：新浪证券-红岸工作室 2月2日，海普瑞跌4.28%，成交额8013.64万元，换手率0.53%，总市值173.73亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 技术面：筹码平均交易成本为11.65元 该股筹码平均交易成本为11.65元，近期筹码减仓，但减仓程度减缓；目前股价靠近支 ...

Group 1 - The core viewpoint is that China's API (Active Pharmaceutical Ingredient) exports are expected to remain relatively stable in total volume by 2025, despite trade changes and price competition, reflecting the industry's competitiveness [1] - In 2026, uncertainties in API trade will persist, with further competition and cooperation between China and India [1] - New technologies, such as synthetic biology, are driving down unit costs and enhancing the global competitiveness of Chinese companies in terms of quality and service efficiency [1] Group 2 - Some API prices have already bottomed out, and the trend of supply clearing is expected to continue, potentially leading to a price rebound due to changes in the competitive landscape and capacity utilization rates [1] - China's innovative pharmaceutical sector is anticipated to see a strong start in 2026, with several significant licensing deals validating technological capabilities [1] - The clinical data in the small nucleic acid drug field continues to validate its potential, accelerating market progress and attracting more leading companies to invest, which may drive the development of the supporting industrial chain [1] Group 3 - In the GLP-1 (Glucagon-like peptide-1) sector, a new pricing system is forming domestically, with rapid growth in overseas oral formulations [1] - Oral autoimmune drugs are also showing significant value [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which focuses on new drug development driven by technological innovation, reflecting the overall trend of innovation in China's pharmaceutical industry [1]

2月2日上午，A股三大指数集体下跌，其中沪指下跌1.02%。截止10:58，科创100ETF华夏 （588800.SH）下跌2.85%。其他宽基指数中，上证50跌0.55%，科创50跌2.24%，创业板50跌1.02%，北 证50跌0.81%。 | 值 | | | 科创100ETF华夏 588800 | | | --- | --- | --- | --- | --- | | 0251125-20260202 (48) 合 | 1.623 | 1.500 | | -0.044(-2.85%) | | .602 | | 委北 | +19.87% | 32581 | | | | 5 | 1.505 | gggg | | | 1.519 | 卖4 | 1.504 | 7395 | | | | 3 | 1.503 | 21057 | | | | 盘2 | 1.502 | 17227 | | | 1.415 | 1 | 1.501 | 10000 | | | | 1 | 1.500 | 22916 | | | 1.311 | 买2 | 1.499 | 19018 | | | | 3 | 1.498 | 28674 | | ...

Group 1 - On January 30, Changshan Pharmaceutical's stock rose by 5.28%, with a trading volume of 1.538 billion yuan [1] - The company had a financing buy amount of 104 million yuan and a financing repayment of 111 million yuan on the same day, resulting in a net financing buy of -7.81 million yuan [1] - As of January 30, the total margin balance for Changshan Pharmaceutical was 2.608 billion yuan, accounting for 5.12% of its circulating market value, which is above the 90th percentile level over the past year [1] Group 2 - As of January 20, the number of shareholders for Changshan Pharmaceutical was 41,400, an increase of 2.88% from the previous period [2] - The average circulating shares per person decreased by 2.79% to 22,148 shares [2] - For the period from January to September 2025, the company reported an operating income of 681 million yuan, a year-on-year decrease of 13.11%, and a net profit attributable to the parent company of -44.82 million yuan, a decrease of 714.77% year-on-year [2] Group 3 - Since its A-share listing, Changshan Pharmaceutical has distributed a total of 181 million yuan in dividends, with 4.5953 million yuan distributed in the last three years [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the sixth largest circulating shareholder, holding 3.8944 million shares, a decrease of 6.6577 million shares from the previous period [3]

Group 1 - The company has a total of 17 new products and over 30 research reserve varieties, with several global patent expirations scheduled between 2028 and 2033 [1] - Some products, such as Vabigatran, Rosuvastatin, and others, are already in the registration submission process, indicating ongoing development efforts [1] - The company plans to maintain multiple new product launches each year, creating a product lineup consisting of mature products, research (registration) products, and reserve products [1] Group 2 - Currently, there is no relevant layout in the innovative drug sector, indicating a focus on other areas [1] - The company's associate, Boya Biotech, primarily engages in the research and production of high-difficulty specialty formulations, which have high industry entry barriers [1] - Future business synergies are expected between the company and Boya Biotech, enhancing overall operational capabilities [1]